Have Insiders Sold Aldeyra Therapeutics Shares Recently?
Have Insiders Sold Aldeyra Therapeutics Shares Recently?
We wouldn't blame Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shareholders if they were a little worried about the fact that Todd Brady, the CEO, President & Director recently netted about US$581k selling shares at an average price of US$3.17. That's a big disposal, and it decreased their holding size by 14%, which is notable but not too bad.
如果Aldeyra Therapeutics, Inc.(纳斯达克股票代码:ALDX)股东对首席执行官、总裁兼董事托德·布雷迪最近以3.17美元的平均价格净出售股票约58.1万美元感到担忧,我们就不会责怪他们。这是一笔巨额出售,它使他们的持股规模减少了14%,这值得注意,但还不错。
Aldeyra Therapeutics Insider Transactions Over The Last Year
去年 Aldeyra Therapeutics 的内幕交易
In fact, the recent sale by Todd Brady was the biggest sale of Aldeyra Therapeutics shares made by an insider individual in the last twelve months, according to our records. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (US$2.77). So it is hard to draw any strong conclusion from it.
实际上,根据我们的记录,托德·布雷迪最近的出售是内部人士在过去十二个月中最大的一次出售Aldeyra Therapeutics股票。尽管内幕抛售是负面的,但对我们来说,如果以较低的价格出售股票,则负面影响更大。一线希望是,这种抛售发生在最新价格(2.77美元)之上。因此,很难从中得出任何强有力的结论。
Insiders in Aldeyra Therapeutics didn't buy any shares in the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
去年,Aldeyra Therapeutics的内部人士没有购买任何股票。您可以看到下图所示的去年的内幕交易(公司和个人)。如果你想确切地知道谁卖了、卖了多少以及何时出售,只需点击下图!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240315/0-514ae452e37d2d63c8796f7d23c8fe01-0-f9953c545f5fc9938ed3db2ddd3da4c1.png/big)
I will like Aldeyra Therapeutics better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
如果我看到一些重大的内幕收购,我会更喜欢Aldeyra Therapeutics。在我们等待的同时,请查看这份免费清单,列出了最近有大量内幕收购的成长型公司。
Does Aldeyra Therapeutics Boast High Insider Ownership?
Aldeyra Therapeutics 是否拥有很高的内部所有权?
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Based on our data, Aldeyra Therapeutics insiders have about 2.4% of the stock, worth approximately US$4.1m. I generally like to see higher levels of ownership.
我喜欢看看内部人士在一家公司拥有多少股票,以帮助我了解他们与内部人士的看法。通常,内部人士的所有权越高,内部人士长期建立公司的可能性就越大。根据我们的数据,Aldeyra Therapeutics内部人士持有该股约2.4%,价值约410万美元。我通常希望看到更高的所有权级别。
What Might The Insider Transactions At Aldeyra Therapeutics Tell Us?
Aldeyra Therapeutics的内幕交易能告诉我们什么?
Insiders sold Aldeyra Therapeutics shares recently, but they didn't buy any. Looking to the last twelve months, our data doesn't show any insider buying. When you combine this with the relatively low insider ownership, we are very cautious about the stock. So we're not rushing to buy, to say the least. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For example, Aldeyra Therapeutics has 3 warning signs (and 1 which is concerning) we think you should know about.
业内人士最近出售了Aldeyra Therapeutics的股票,但他们没有购买任何股票。展望过去的十二个月,我们的数据并未显示任何内幕买盘。当你将其与相对较低的内部所有权相结合时,我们对这只股票非常谨慎。因此,至少可以说,我们并不急于购买。因此,这些内幕交易可以帮助我们建立有关股票的论点,但也值得了解这家公司面临的风险。例如,Aldeyra Therapeutics有3个警告信号(其中一个令人担忧),我们认为你应该知道。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,来看看这份有趣的公司的免费清单吧。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。